(Comparative)
Notably, in June 2021, the FDA approved semaglutide for chronic weight management in adults dealing with general obesity or overweight and presenting at least one weight-related condition [Reference Davies, Faerch, Jeppesen, Pakseresht, Pedersen and Perreault45]
But its a long-term play: Payers must analyze and establish longer-term ROI Even if payers actively want to keep up with the wave of demand for GLP-1s to treat obesity, they ultimately must convince plan sponsors to buy in
While often taken for granted, these charts play a crucial role in helping patients achieve their weight loss goals by guiding healthcare professionals and pharmacists through the precise steps needed to mix and administer the medication correctly
Consistent timing is critical for optimal absorption
Multifactor authentication, encryption, and segregated payment flows should be nonnegotiable